Yamagata University Hospital
Welcome,         Profile    Billing    Logout  
 14 Trials 
34 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Delage, Robert
NCT05413915: Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Recruiting
3
164
Canada
Asciminib, ABL-001, Imatinib, Imatinib mesylate
Sarit Assouline, Novartis
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia in Remission
12/25
12/25
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
Jurczak, Wojciech
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
ACALLO, NCT04716075 / 2018-003465-33: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

Completed
2
29
Europe
Acalabrutinib 2x100 MG Oral Capsule + alloSCT
Polish Lymphoma Research Group, AstraZeneca
Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma, Adverse Event, Response Rate
06/24
07/24
JASPIS-01, NCT06534437: MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting
2
178
Europe
MEN1703, SEL24, Glofitamab
Ryvu Therapeutics SA, Menarini Group
Non-Hodgkin Lymphoma, B-cell
12/26
12/26
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
17-BI-1206-02, NCT03571568 / 2018-000444-26: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Recruiting
1/2
140
Europe, US, RoW
BI-1206, Rituximab, Ruxience, Acalabrutinib, Calquence
BioInvent International AB
Indolent B-Cell Non-Hodgkin Lymphoma
09/26
09/26
BV-MAZOVIA, NCT05100056: A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Recruiting
N/A
70
Europe
No Intervention
Takeda
Hodgkin Lymphoma
06/26
06/26
Sonoda, Yukihiko
RE-GEND, NCT02761070: Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

Active, not recruiting
3
146
Japan
Temozolomide, Temodar, Temodal, Bevacizumab, Avastin
Kyorin University, Japan Clinical Oncology Group
Glioblastoma, Recurrence, Progression
11/25
11/25
Hasegawa, Kosei
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
GOTIC-025, NCT04641728: Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Active, not recruiting
2
28
Japan
Pembrolizumab, KEYTRUDA, Olaparib, LYNPARZA
Saitama Medical University International Medical Center, Tokyo University, National Cancer Center, Japan, Cancer Institute Hospital, Japan, Aichi Cancer Center
Cervical Cancer
12/22
12/23
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
RUBY-J, NCT06317311: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Recruiting
2
36
Japan
Dostarlimab, Carboplatin, Paclitaxel
GlaxoSmithKline
Carcinoma
07/26
08/27
SaINT-ov02, NCT05158062: Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Recruiting
2
35
Japan
pembrolizumab, KEYTRUDA, olaparib, LYNPARZA, bevacizumab, AVASTIN, carboplatin, paclitaxel, docetaxel
Kosei Hasegawa, MD, PhD
Carcinoma, Ovarian Epithelial
11/24
11/24
NCT06555744: A Study of ZW191 in Participants With Solid Tumors

Recruiting
1
145
Japan, US, RoW
ZW191
Zymeworks BC Inc.
Advanced Solid Tumors
12/26
01/27
Sanada, Nobuhito
NCT04362007: A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Terminated
1/2
61
Japan
ASTX660
Otsuka Pharmaceutical Co., Ltd.
Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
11/24
11/24
NCT04649073: Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1/2
49
Japan
OPC-415
Otsuka Pharmaceutical Co., Ltd.
Multiple Myeloma (MM)
01/27
01/41
NCT04049825: A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Active, not recruiting
1
36
Japan
OPB-111077
Otsuka Pharmaceutical Co., Ltd.
Relapsed or Refractory Diffuse Large B-cell Lymphoma
03/25
03/25
NCT03906695: Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

Active, not recruiting
1
30
Japan
ASTX727
Otsuka Pharmaceutical Co., Ltd.
Lower-risk Myelodysplastic
01/26
01/26
NCT04608110: A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome

Recruiting
1
40
Japan
ASTX030
Otsuka Pharmaceutical Co., Ltd.
Myelodysplastic Syndrome (MDS)
04/25
05/25
Tobai, Tomomi
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28

Download Options